Symbol="ABUS"
AssetType="Common Stock"
Name="Arbutus Biopharma Corp"
Description="Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania."
CIK="1447028"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="100-8900 GLENLYON PARKWAY, BURNABY, BC, CA"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="346389000"
EBITDA="-73384000"
PERatio="None"
PEGRatio="0"
BookValue="0.807"
DividendPerShare="0"
DividendYield="0"
EPS="-0.44"
RevenuePerShareTTM="0.148"
ProfitMargin="0"
OperatingMarginTTM="-3.174"
ReturnOnAssetsTTM="-0.238"
ReturnOnEquityTTM="-0.507"
RevenueTTM="23535000"
GrossProfitTTM="-45389000"
DilutedEPSTTM="-0.44"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.673"
AnalystTargetPrice="5.4"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="11.68"
PriceToBookRatio="2.806"
EVToRevenue="7.67"
EVToEBITDA="-4.533"
Beta="2.102"
num_52WeekHigh="3.15"
num_52WeekLow="1.85"
num_50DayMovingAverage="2.243"
num_200DayMovingAverage="2.581"
SharesOutstanding="166134000"
DividendDate="None"
ExDividendDate="None"
symbol="ABUS"
open="2.05"
high="2.12"
low="2.04"
price="2.06"
volume="508351.00"
latest_trading_day="2023-08-18"
previous_close="2.07"
change="-0.01"
change_percent="-0.4831%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="81"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="19"
Volume_recent_avg="680519"
Change_recent_avg="-0.01"
Delta_recent_avg="0.09"
Variance_recent_avg="0.05"
Change_ratio_recent_avg="-0.31"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="19"
Aroon_momentum_negative="81"
image_negative_thumbnail_id_1="1144"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0177.jpeg"
image_negative_thumbnail_id_2="1102"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0135.jpeg"
image_neutral_thumbnail_id_1="581"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0018.jpeg"
image_neutral_thumbnail_id_2="583"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0016.jpeg"
image_positive_thumbnail_id_1="1011"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0173.jpeg"
image_positive_thumbnail_id_2="986"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0148.jpeg"
image_professor_thumbnail_id_1="1168"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
image_professor_thumbnail_id_2="1182"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0016.jpeg"
